Limited Submission Funding Opportunities – updated 3/27/20

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of $50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process
Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:
1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)
   MGH LOI Deadline: 3/27/20
   NIH LOI Deadline: 4/27/20
   NIH Application Deadline: 5/28/20

   The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIBIB R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
Limited Submission Funding Opportunities – updated 3/27/20

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on *Courses for Skills Development*.

This FOA seeks to support programs that include innovative approaches to enhance biomedical engineering design education to ensure a future workforce that can meet the nation’s needs in biomedical research and healthcare technologies.

Applications are encouraged from institutions that propose to establish new or to enhance existing team-based design courses or programs in undergraduate biomedical engineering departments or other degree-granting programs with biomedical engineering tracks/minors. This FOA targets the education of undergraduate biomedical engineering/bioengineering students in a team-based environment. While current best practices such as multidisciplinary/interdisciplinary education, introduction to the regulatory pathway and other issues related to the commercialization of medical devices, and clinical immersion remain encouraged components of a strong BME program, this FOA also challenges institutions to propose other novel, innovative and/or ground-breaking activities that can form the basis of the next generation of biomedical engineering design education.

2. **1907 Trailblazer Award**
   [https://www.1907-research.org/apply](https://www.1907-research.org/apply)

   **MGH LOI Deadline: 4/15/20**
   **Sponsor Application Deadline: 5/31/20**

   The 1907 Trailblazer Award was established to encourage high-impact, step-change approaches to research in the brain and mind sciences for mental health. In addition to supporting a specific research project, the Award intends to increase the size of the talent pool of early career investigators researching causes & cures for mental illness. We promote these aims by providing a US$100,000 research gift on an unrestricted basis, a US$20,000 prize to enhance the economic security of the scientist, and travel & expense coverage for attendance at two annual meetings.

   Projects must be grounded in the study of biological mechanisms underlying brain function, cognitive processes, and/or consciousness. We support projects for basic science in addition to near-term applications (e.g. disruptive technologies and potential clinical interventions).

   MGH may select **two candidates** for this opportunity.

   - Applicants must be within ten years of the date when PhD/MD degree was awarded (whichever came later and with exceptions for maternity leave, paternity leave and other excused absences)
   - Applicants will have demonstrated independence from senior colleagues. They must be able to initiate and direct their own research as principal investigator, have full responsibility for running their labs and full control of their research funds.
   - Applicants will have a strong track record of scientific publications relevant to their research program
   - Research applications may be related to but cannot be identical to any other currently funded projects

   **In addition to the basic requirements for an ECOR letter of intent, please be sure to include the following information:**
   1. What is the novel idea and what is the potential impact of your idea to the field?
   2. What tools, resources, and relationships do you have to enable you to complete the research?
3. **Childhood Asthma in Urban Settings – Clinical Research Centers (U01 Clinical Trial Optional)**
   MGH LOI Deadline: 4/16/20
   NIH LOI Deadline: 5/19/20
   NIH Application Deadline: 6/19/20

   The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the NIAID Childhood Asthma in Urban Settings Clinical Research Network Clinical Research Centers (CAUSE-CRCs). The CAUSE-CRCs will conduct both network-wide and site-specific clinical studies and trials with the ultimate goal of developing effective asthma treatment or prevention approaches applicable to children residing in low-income urban settings. For network-wide clinical research projects and other network functions, the CAUSE-CRCs will work closely with the CAUSE Leadership Center (CAUSE-LC).

4. **Childhood Asthma in Urban Settings – Clinical Research Network – Leadership Center (UM1 Clinical Trial Required)**
   MGH LOI Deadline: 4/16/20
   NIH LOI Deadline: 5/19/20
   NIH Application Deadline: 6/19/20

   The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the NIAID Childhood Asthma in Urban Settings Clinical Research Network Leadership Center (CAUSE-LC). The CAUSE-LC will provide the overall scientific strategy and organizational structure to the CAUSE Clinical Research Network and will interact closely with the CAUSE Clinical Research Centers (CAUSE-CRCs) to support the conduct of multi-site clinical studies and trials with the ultimate goal of developing effective interventions or asthma prevention approaches applicable to children residing in low-income urban settings.

5. **Centers for AIDS Research (P30 Clinical Trial Not Allowed)**
   MGH LOI Deadline: 5/20/20
   NIH LOI Deadline: 6/29/20
   NIH Application Deadline: 7/28/20

   The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research.
Limited Submission Funding Opportunities – updated 3/27/20

6. Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed)
   MGH LOI Deadline: 5/20/20
   NIH LOI Deadline: 6/29/20
   NIH Application Deadline: 7/28/20

   The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. D-CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. Additionally, D-CFARs provide support to assist investigators in the development of a competitive standard CFAR. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research.

7. Population Dynamics Centers Research Infrastructure Program FY 2021 (P2C Clinical Trial Not Allowed)
   MGH LOI Deadline: 5/27/20
   NIH LOI Deadline: 6/30/20
   NIH Application Deadline: 7/30/20

   The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support.

8. NIAMS Skin Biology and Diseases Resource-based Centers (P30 – Clinical Trial Not Allowed)
   MGH LOI Deadline: 6/01/20
   NIH LOI Deadline: 7/11/20
   NIH Application Deadline: 8/11/20

   The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Resource-based Centers Program (P30) for research areas within its mission in skin biology and diseases research. The Resource-based Centers will provide critical research infrastructure, shared facilities, services, and/or resources to groups of investigators conducting research on skin biology and diseases, enabling them to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively, with the broad overall goal of accelerating, enriching, and enhancing the effectiveness of ongoing basic, translational, and clinical research and promoting new research within the NIAMS mission.
9. NIAMS Resource-based Centers for Bone, Muscle, and Orthopedic Research (P30 – Clinical Trial Not Allowed)
   MGH LOI Deadline: 6/08/20
   NIH LOI Deadline: 7/11/20
   NIH Application Deadline: 8/11/20

   The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Resource-based Centers Program (P30) for research areas within its mission in bone, muscle and orthopaedic research. The Resource-based Centers will provide critical research infrastructure, shared facilities, services, and/or resources to groups of investigators conducting research on bone, muscle and orthopaedic biology and diseases, enabling them to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively, with the broad overall goal of accelerating, enriching, and enhancing the effectiveness of ongoing basic, translational, and clinical research and promoting new research within these areas of NIAMS mission.

10. Artificial Intelligence and Technology Collaboratories for Aging Research (P30 – Clinical Trial Optional)
    MGH LOI Deadline: 7/27/20
    NIH LOI Deadline: 9/01/20
    NIH Application Deadline: 10/01/20

    This Funding Opportunity Announcement (FOA) invites applications for the Artificial Intelligence and Technology Collaboratories (AITC) for Aging Research program. The AITC program will serve as a national resource to promote the development and implementation of artificial intelligence approaches and technology through demonstration projects to improve care and health outcomes for older Americans, including persons with dementia (PWD) and their caregivers.